0001415889-24-008788.txt : 20240320 0001415889-24-008788.hdr.sgml : 20240320 20240320195752 ACCESSION NUMBER: 0001415889-24-008788 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240313 FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kim Jae B. CENTRAL INDEX KEY: 0001819159 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40288 FILM NUMBER: 24769104 MAIL ADDRESS: STREET 1: C/O AVIDITY BIOSCIENCES, INC. STREET 2: 10975 N. TORREY PINES RD., SUITE 150 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Design Therapeutics, Inc. CENTRAL INDEX KEY: 0001807120 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 823929248 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6005 HIDDEN VALLEY ROAD STREET 2: SUITE 110 CITY: CARLSBAD STATE: CA ZIP: 92011 BUSINESS PHONE: 858-293-4900 MAIL ADDRESS: STREET 1: 6005 HIDDEN VALLEY ROAD STREET 2: SUITE 110 CITY: CARLSBAD STATE: CA ZIP: 92011 3 1 form3-03202024_110345.xml X0206 3 2024-03-13 0 0001807120 Design Therapeutics, Inc. DSGN 0001819159 Kim Jae B. C/O DESIGN THERAPEUTICS, INC. 6005 HIDDEN VALLEY ROAD, SUITE 110 CARLSBAD CA 92011 false true false false Chief Medical Officer Common Stock 4756 D Stock Option (right to buy) 12.77 2032-01-31 Common Stock 315000 D Stock Option (right to buy) 7.97 2033-01-31 Common Stock 115000 D Stock Option (right to buy) 2.54 2034-01-01 Common Stock 175000 D The shares subject to the option will vest as follows: 25% of the shares vested on January 24, 2023, and the balance will vest in equal monthly installments thereafter over a three year period. The shares subject to the option will vest as follows: 20% of the shares vested on February 1, 2024, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2025, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. /s/ Mustapha Parekh, Attorney-in-Fact 2024-03-20 EX-24 2 ex24-03202024_110346.htm ex24-03202024_110346.htm


POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Sean Jeffries and Mustapha Parekh of Design Therapeutics, Inc. (the “Company”), signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

(1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of March 2024.



/s/ Jae B. Kim


Jae B. Kim